INDRANIB quarterly results and annual financials: sales, operating profit, OPM, net profit, EPS, balance sheet, cash flow and ratios like ROCE, with YoY and QoQ growth.
Indrayani Biotech Ltd reported sales of ₹37.71 Cr, operating profit of ₹1.46 Cr (OPM 3.87%) and net profit of ₹0.54 Cr for the quarter ended Jun 2026. Figures in ₹ crore, consolidated where available.
INDRANIB quarterly results (₹ Cr)
Metric
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sales
30.81
17.32
50.57
29.1
35.95
35.01
37.76
37.71
YoY Sales growth
-23.81
-55.69
13.95
-7.71
16.68
102.14
-25.33
29.59
Expenses
25.7
14.4
56.31
26.92
33.5
32.22
35.54
36.25
Operating Profit
5.11
2.92
-5.74
2.18
2.45
2.79
2.22
1.46
OPM
16.59%
16.86%
-11.35%
7.49%
6.82%
7.97%
5.88%
3.87%
Other Income
0.3
0
2.78
1.06
1.8
0.83
0.88
1.59
Interest
1.42
1.03
7.07
2.17
1.89
2.47
3.08
1.37
Depreciation
2.79
1.46
-1.72
0.86
1.3
1.01
1.13
1.1
Profit before tax
1.2
0.43
-8.31
0.21
1.06
0.14
-1.11
0.58
Tax
-1.67%
18.6%
2.53%
23.81%
14.15%
21.43%
-187.39%
8.62%
Net Profit
1.22
0.35
-8.53
0.16
0.91
0.12
0.98
0.54
EPS in Rs
0.27
0.05
-1.87
0.04
0.09
0.03
0.22
0.07
INDRANIB profit & loss, annual (₹ Cr)
Metric
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
TTM
Sales
61
163
165
130
138
146
Sales growth
195
165
2
-21
6
15
Expenses
54
145
142
124
128
138
Operating Profit
7
17
24
6
10
9
OPM
11%
11%
14%
4.9%
7%
6%
Other Income
0
4
1
3
5
5
Interest
2
6
10
12
10
9
Depreciation
1
3
4
3
4
5
Profit before tax
4
12
11
-6
0
1
Tax
0%
3%
5%
6%
-620%
-
Net Profit
4
12
10
-6
2
3
EPS in Rs
1.3
2.56
1.4
-1.34
0.47
0.41
Dividend Payout
0%
0%
0%
0%
0%
-
INDRANIB balance sheet (₹ Cr)
Metric
Mar 2023
Mar 2024
Mar 2025
Sep 2025
Mar 2026
Equity Capital
34
46
46
46
46
Reserves
12
22
27
30
27
Borrowings
79
113
137
146
128
Other Liabilities
31
54
58
52
52
Total Liabilities
156
234
268
274
253
Fixed Assets
57
62
58
62
60
CWIP
14
20
26
23
27
Investments
0
0
0
0
0
Other Assets
85
151
184
189
166
Total Assets
156
234
268
274
253
INDRANIB cash flows (₹ Cr)
Metric
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Cash from Operating Activity
4
16
-30
-7
32
Cash from Investing Activity
-1
-47
-16
25
-13
Cash from Financing Activity
-3
33
44
-18
-15
Net Cash Flow
1
2
-2
0
4
Free Cash Flow
3
-25
-47
-8
23
CFO/OP
61%
94%
-128%
-124%
328%
CFO/EBITDAShare of operating profit converting into cash: CFO (before tax) / Operating Profit